Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line
PLOS ONE · 28.09.2023 · 18 (9) · e0291981
DOI: 10.1371/journal.pone.0291981 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 28.09.2023. Verfasst von Zainab Lafi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacological and Diagnostic Research Centre, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan. Hauptthemen laut MEDLINE: Doxorubicin, Disulfiram, Hydralazine, Breast Neoplasms. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Disulfiram and hydralazine have recently been reported to have anti-cancer action, and repositioned to be used as adjuvant in cancer therapy. Chemotherapy combined with other medications, such as those that affect the immune system or epigenetic cell profile, can overcome resistance with fewer adverse effects compared to chemotherapy alone. In the present study, a combination of doxorubicin (DOX) with hydrazine (Hyd) and disulfiram (Dis), as a triple treatment, was evaluated against wild-type and DOX-resistant MCF-7 breast cancer cell line. Both wild-type MCF-7 cell line (MCF-7_WT) and DOX-resistant MCF-7 cell line (MCF-7_DoxR) were treated with different combination ratios of DOX, Dis, and Hyd followed by measuring the cell viability using the MTT assay. Synergism was determined using a combination index, isobologram analysis, and dose-reducing index. The anti-proliferation activity and mechanism of the triple combination were investigated by apoptosis analysis. The results showed a reduction in the IC 50 values of DOX in MCF-7_WT cells (from 0.24 μM to 0.012 μM) and MCF-7_DoxR cells (from 1.13 μM to 0.44 μM) when treated with Dis (0.03μM), and Hyd (20μM) combination. Moreover, The triple combination DOX/Hyd/Dis induced significant apoptosis in both MCF-7_WT and MCF-7_DoxR cells compared to DOX alone. The triple combination of DOX, Dis, and Hyd showed a synergistic drugs combination to decrease the DOX dose needed to kill both MCF-7_WT and MCF-7_DoxR cancer cells and enhanced chemosensitivity to DOX.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmacological and Diagnostic Research Centre, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
- Cell Therapy Center, The University of Jordan, Amman, Jordan.
- Department of Nanoscience, Joint School of Nanoscience and Nanoengineering, University of North Carolina at Greensboro, Greensboro, NC, United States of America.
ORCID-Profile: Walhan Alshaer
Zitieren
APA
Lafi, Z., Alshaer, W., Gharaibeh, L., Alqudah, D. A., AlQuaissi, B., Bashaireh, B., & Ibrahim, A. A. (2023). Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line. PLOS ONE, 18(9), e0291981. https://doi.org/10.1371/journal.pone.0291981
Vancouver
Lafi Z, Alshaer W, Gharaibeh L, Alqudah DA, AlQuaissi B, Bashaireh B, et al. Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line. PLOS ONE. 2023;18(9):e0291981. doi:10.1371/journal.pone.0291981
BibTeX
@article{Lafi2023,
author = {Lafi, Zainab and Alshaer, Walhan and Gharaibeh, Lobna and Alqudah, Dana A and AlQuaissi, Baidaa and Bashaireh, Banan and Ibrahim, Abed Alqader},
title = {Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {9},
pages = {e0291981},
doi = {10.1371/journal.pone.0291981}
}
EUVIMED